Large TAILORx outcomes study demonstrates 99% of patients with low Oncotype DX® Recurrence Score® results were breast cancer relapse-free following five years of hormone therapy alone
- Study results published today in the New England Journal of Medicine
- Additional clinical outcomes from large patient registry confirm accuracy of Oncotype DX test in guiding treatment decisions
GENEVA, Sept. 28, 2015 /PRNewswire/ -- Genomic Health today announced the presentation of the first results1 from the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx, a large, prospectively conducted trial designed and conducted by the ECOG-ACRIN Cancer Research Group under the sponsorship of the U.S. National Cancer Institute (NCI). The study demonstrated that a group of trial participants with early-stage breast cancer and with low Oncotype DX Recurrence Score results of 10 or less who received hormonal therapy alone without chemotherapy had less than a 1% chance of distant recurrence at five years.
Presented at the 2015 European Cancer Congress (ECC2015), results from a group of 1,626 patients with a Recurrence Score result between 0 and 10 demonstrated that 99.3%of node-negative, estrogen receptor-positive, HER2-negative patients who met accepted guidelines for recommending chemotherapy in addition to hormonal therapy had no distant recurrence at five years after treatment with hormonal therapy alone. Outcomes were excellent irrespective of patient age, tumour size, and tumour grade.
"This is the first prospectively conducted clinical trial evaluating this multi-gene test – or any breast cancer multi-gene test for that matter – in which patients with early stage breast cancer were uniformly treated based on their test results," said Joseph Sparano, MD, Montefiore Medical Center, Bronx, NY, and ECOG-ACRIN study chair. "The compelling results seen in this global study provide unequivocal evidence supporting the clinical utility of Oncotype DX to risk-stratify patients with early stage breast cancer."
The trial enrolled 10,273 patients across 1,182 community-based medical facilities and major cancer centres in the United States, Canada, Peru, Ireland, Australia and New Zealand. TAILORx used the Oncotype DX test on every patient to quantify individual risk of recurrence in order to assign them to the appropriate treatment. The data safety monitoring board of the TAILORx trial, as mandated by the study protocol, will continue to monitor outcomes in patients with a Recurrence Score result of 11 to 25 randomised to chemo-endocrine therapy or endocrine therapy alone. Previous Oncotype DX studies have already confirmed the benefit of adjuvant chemotherapy for those in the high Recurrence Score range.
Oncotype DX Recurrence Score used to select treatment and optimise outcomes
Complementing the data from TAILORx, Genomic Health announced the presentation of real-world clinical outcomes from a large cohort of patients in the Clalit registry2. Over half of the 930 patients in the analysis were identified as low-risk and were treated with hormonal therapy alone based on Recurrence Score results. A follow-up, nearly six-years later, showed very high survival rates (99.8%) and low distant recurrence rates (0.5%) in this patient group.
Survival and recurrence rates in patients with high Recurrence Score results, most of whom received chemotherapy, were 96% and 4% respectively while for patients in the intermediate group survival and recurrence rates were 98.8% and 2.3% respectively.
"Results from our registry suggest that adding molecular information provided by the Oncotype DX test is essential in order to spare low-risk patients the toxicity and side effects of chemotherapy," said Prof Salomon Stemmer, Lead investigator of the study, Department of Oncology, Davidoff Center, Rabin Medical Center affiliated to Tel Aviv University, Israel. "Knowing that Oncotype DX is predictive of chemotherapy benefit gave us confidence to move forward with appropriate, individualised treatment for each patient."
Clalit is an analysis of medical records of patients receiving the Oncotype DX breast cancer test in four medical centres within Clalit Health Services, the largest health services organisation in Israel. Researchers will continue to follow patients and report results and outcomes.
The Oncotype DX breast cancer test is the only genomic test validated for its ability to predict the likelihood of chemotherapy benefit as well as risk of recurrence in early-stage breast cancer.
Healthcare systems across Europe are recognising the value of the test, which is incorporated in all major international clinical guidelines. Most recently, the National Health Service (NHS) in England agreed to an access programme for the Oncotype DX breast cancer test. The access programme allows NHS hospitals to implement the National Institute for Health and Care Excellence's (NICE) guidance, which recommends only the Oncotype DX breast cancer test in routine clinical use for assisting in chemotherapy treatment decisions for patients with certain types of early breast cancer. Other European countries that reimburse the test include Switzerland, Ireland, Greece and Spain.
About Genomic Health
Genomic Health, Inc. is a world-leading provider of genomic-based diagnostic tests that inform treatment decisions and help to ensure each patient receives appropriate treatment for early stage cancer. The company applies its state-of-the-art scientific and commercial expertise and infrastructure to translate significant amounts of genomic data into clinically actionable results for treatment planning throughout the cancer patient's journey; from screening and surveillance, through diagnosis and treatment selection. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com. To learn more about Oncotype DX, visit: www.OncotypeDX.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the ability of test results to change treatment decisions; the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the year ended June 30, 2015. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, and Recurrence Score, are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
1 J. Sparano "Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low- risk registry" (Abstract #5BA)
2 S. Stemmer "First prospective outcome data in 930 patients with more than 5-year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-Gene Recurrence Score" (Abstract #1963)
Logo - http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
Share this article